BIOMOTI

• 72190 - Other research and experimental development on natural sciences and engineering

We are developing Oncojans, a promising new class of drug-loaded, long-acting particles, designed to precisely target and gain entry to cancer cells. In the tumours, they slowly release drugs at the point of need whilst sparing healthy tissue. Early preclinical studies for BMT101, our lead ovarian cancer candidate, compared to the clinical standard of care, paclitaxel, have shown very encouraging results including over 10-fold increases in drug concentration in tumours, 65-fold reductions in tumour burden, a 4-fold increase in survival and a reduction in toxicity. This includes work in immunocompetent models of advanced ovarian cancer disease. BMT101 and future engineered Oncojans could be transformational in the treatment of cancer patients.

Also known as: BIOMOTI LIMITED, BioMoti Ltd

Registration numbers: 06926173 (CH)

Primary location: WARWICK UNITED KINGDOM